Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
DOI: 10.1038/jhh.2008.57 Morton C, Hickey-Dwyer M (1992): Cortical blindness after nifedipine treatment
The Bottom Line Weight loss is a common goal for new moms, but the safety of GLP-1 drugs like semaglutide during breastfeeding is still not fully understood
While irritability is not officially listed as a common side effect, the way semaglutide interacts with certain hormones and brain functions may explain why some people feel more easily frustrated, anxious, or emotionally sensitive while using the medication
Preclinical signals regarding potential effects on thyroid C-cells (observed with GLP-1 agonists as a class), as well as theoretical questions about bone metabolism and cardiovascular function, are being monitored in ongoing trials
Doi:10.1056/NEJMoa2307563 Wilding JPH, et al
Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials
